Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Desonide + polymyxin B is a topical combination drug consisting of desonide, a low-potency corticosteroid, and polymyxin B, an antibiotic. Desonide acts by activating glucocorticoid receptors in the skin to reduce inflammation, redness, swelling, and itching associated with various dermatological conditions such as eczema and dermatitis. Polymyxin B is a bactericidal antibiotic that disrupts the cell membrane of susceptible Gram-negative bacteria by binding to their phospholipids, leading to cell death. This combination may be used for inflammatory skin conditions at risk of secondary bacterial infection or where both anti-inflammatory and antibacterial actions are desired[8][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on desonide + polymyxin B.